Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aldeyra Therapeutics

6.56
-0.1050-1.58%
Volume:377.10K
Turnover:2.44M
Market Cap:391.69M
PE:-6.99
High:6.69
Open:6.69
Low:6.22
Close:6.67
Loading ...

Company Profile

Company Name:
Aldeyra Therapeutics
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
9
Office Location:
131 Hartwell Avenue,Suite 320,Lexington,Massachusetts,United States
Zip Code:
02421
Fax:
339 674 6495
Introduction:
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Directors

Name
Position
Richard H. Douglas
Director,Chairman
Todd C. Brady
President and Chief Executive Officer,Director
Ben R. Bronstein
Director
Gary Phillips
Director
Martin J. Joyce
Director
Nancy Miller Rich
Director
Neal Walker
Director

Shareholders

Name
Position
Todd C. Brady
President and Chief Executive Officer,Director
Bruce Greenberg
Senior Vice President Finance, Interim Chief Financial Officer
Stephen G. Machatha
Chief Development Officer